RLS Global AB (publ) Interim Report, Q1, 2023
JANUARY 1st - MARCH 31st (Previous year in brackets)
- Net sales amounted to TSEK 89 (TSEK 305)
- Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK -5,3)
- Earnings per share after dilution at SEK -0,09 (SEK 0,07)
- Cash flow from operating activities amounted to TSEK -7 084 (TSEK -6 730)
- Liquid assets at the end of the period MSEK 13,4 (MSEK 4,7)
- Equity ratio was 82 % (77 %)
- An extra AGM was held 9 February.
- Lars Johansson was elected Board Member and Chairman of the Board at the extra AGM.
- Wounds UK publishes the peer-reviewed article "The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel". The article concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity, in vitro, compared to other debridement products and techniques.
- The UK MHRA (Medicines & Healthcare products Regulatory Agency) has approved RLS' application to extend the current clinical study for pressure ulcers to UK.
- Eva Jagenheim leaves her role as CFO in RLS Global AB. She will remain in service during her notice period, at latest to October, to ensure a smooth transition to her successor.
The Interim Report Q1, 2023, is enclosed and is also available at https://rls.global/financial-information/financial-reports-eng/
Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on May 31st 2023.